{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:46:07Z","timestamp":1771008367825,"version":"3.50.1"},"reference-count":74,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The epidemic curve of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is silently rising again. Worldwide, the dominant SARS-CoV-2 variant of concern (VOC) is Omicron, and its virological characteristics, such as transmissibility, pathogenicity, and resistance to both vaccine- and infection-induced immunity as well as antiviral drugs, are an urgent public health concern. The Omicron variant has five major sub-lineages; as of February 2022, the BA.2 lineage has been detected in several European and Asian countries, becoming the predominant variant and the real antagonist of the ongoing surge. Hence, although global attention is currently focused on dramatic, historically significant events and the multi-country monkeypox outbreak, this new epidemic is unlikely to fade away in silence. Many aspects of this lineage are still unclear and controversial, but its apparent replication advantage and higher transmissibility, as well as its ability to escape neutralizing antibodies induced by vaccination and previous infection, are rising global concerns. Herein, we review the latest publications and the most recent available literature on the BA.2 lineage of the Omicron variant.<\/jats:p>","DOI":"10.3390\/ijms23137315","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:21:50Z","timestamp":1656634910000},"page":"7315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Omicron BA.2 Lineage, the \u201cStealth\u201d Variant: Is It Truly a Silent Epidemic? A Literature Review"],"prefix":"10.3390","volume":"23","author":[{"given":"Giorgio","family":"Tiecco","sequence":"first","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Storti","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Arsuffi","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Degli Antoni","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-5379","authenticated-orcid":false,"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-9100","authenticated-orcid":false,"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"ref_1","unstructured":"WHO (2022, June 09). Weekly Epidemiological Update on COVID-19. 8 June 2022. Available online: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---8-june-2022."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tiecco, G., Storti, S., Degli, M.A., Foc\u00e0, E., Castelli, F., and Quiros-Roldan, E. (2022). Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23041987"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.cell.2022.04.035","article-title":"Virological Characteristics of the SARS-CoV-2 Omicron BA.2 Spike","volume":"185","author":"Yamasoba","year":"2022","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kannan, S.R., Spratt, A.N., Sharma, K., Goyal, R., S\u00f6nnerborg, A., Apparsundaram, S., Lorson, C.L., Byrareddy, S.N., and Singh, K. (2022). Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202204.0120.v1"},{"key":"ref_6","unstructured":"Public Health Ontario (2022, June 09). COVID-19 Omicron Variant Sub-Lineage BA.2: Evidence and Risk Assessment (Up to Date as of 19 April 2022). Available online: Https:\/\/Www.Publichealthontario.ca\/-\/Media\/Documents\/NCoV\/Voc\/Covid-19-Omicron-Risk-Assessment.Pdf?Sc_lang=en."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/d41586-022-01466-9","article-title":"Why Call It BA.2.12.1? A Guide to the Tangled Omicron Family","volume":"606","author":"Maxmen","year":"2022","journal-title":"Nature"},{"key":"ref_8","unstructured":"UK Health Security Agency (2022, June 09). Investigation of SARS-CoV-2 Variants: Technical Briefings, Available online: https:\/\/www.gov.uk\/government\/publications\/investigation-of-sars-cov-2-variants-technical-briefings."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1002\/mco2.130","article-title":"Antigenicity Comparison of SARS-CoV-2 Omicron Sublineages with Other Variants Contained Multiple Mutations in RBD","volume":"3","author":"Li","year":"2022","journal-title":"MedComm"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-020-16567-0","article-title":"Vulnerabilities in Coronavirus Glycan Shields despite Extensive Glycosylation","volume":"11","author":"Watanabe","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41422-021-00545-2","article-title":"O-Glycosylation Pattern of the SARS-CoV-2 Spike Protein Reveals an \u201cO-Follow-N\u201d Rule","volume":"31","author":"Tian","year":"2021","journal-title":"Cell Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2200181","DOI":"10.2807\/1560-7917.ES.2022.27.10.2200181","article-title":"Molecular Epidemiology of the SARS-CoV-2 Variant Omicron BA.2 Sub-Lineage in Denmark, 29 November 2021 to 2 January 2022","volume":"27","author":"Fonager","year":"2022","journal-title":"Eurosurveillance"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kumar, S., Karuppanan, K., and Subramaniam, G. (2022). Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-Based Computational Assessment. J. Med. Virol., in press.","DOI":"10.1101\/2022.02.11.480029"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mykytyn, A.Z., Rissmann, M., Kok, A., Rosu, M.E., Schipper, D., Breugem, T.I., van den Doel, P.B., Chandler, F., Bestebroer, T., and de Wit, M. (2022). Omicron BA.1 and BA.2 Are Antigenically Distinct SARS-CoV-2 Variants. BioRxiv.","DOI":"10.1101\/2022.02.23.481644"},{"key":"ref_16","unstructured":"ECDC (2022, June 09). Country Overview Report: Week 22. Available online: https:\/\/covid19-country-overviews.ecdc.europa.eu\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/d41586-022-00471-2","article-title":"Why Does the Omicron Sub-Variant Spread Faster than the Original?","volume":"602","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(21)00542-7","article-title":"SARS-CoV-2 Infection and Vaccine Effectiveness in England (REACT-1): A Series of Cross-Sectional Random Community Surveys","volume":"10","author":"Wang","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"abq4411","DOI":"10.1126\/science.abq4411","article-title":"Twin Peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 Epidemics in England","volume":"376","author":"Elliott","year":"2022","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Stegger, M., Edslev, S.M., Sieber, R.N., Ingham, A.C., Ng, K.L., Tang, M.-H.E., Alexandersen, S., Fonager, J., Legarth, R., and Utko, M. (2022). Occurrence and Significance of Omicron BA.1 Infection Followed by BA.2 Reinfection. BioRxiv.","DOI":"10.1101\/2022.02.19.22271112"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","article-title":"SARS-CoV-2 Omicron Triggers Cross-Reactive Neutralization and Fc Effector Functions in Previously Vaccinated, but Not Unvaccinated, Individuals","volume":"30","author":"Richardson","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hirose, R., Itoh, Y., Ikegaya, H., Miyazaki, H., Watanabe, N., Yoshida, T., Bandou, R., Daidoji, T., and Nakaya, T. (2022). Differences in Environmental Stability among SARS-CoV-2 Variants of Concern: Both Omicron BA.1 and BA.2 Have Higher Stability. Clin. Microbiol. Infect., in press.","DOI":"10.1101\/2022.01.18.476607"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S1473-3099(22)00224-9","article-title":"Comparable Neutralisation Evasion of SARS-CoV-2 Omicron Subvariants BA.1, BA.2, and BA.3","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1038\/s41467-022-30580-5","article-title":"Cross-Neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2","volume":"13","author":"Zou","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Miller, N.L., Clark, T., Raman, R., and Sasisekharan, R. (2022). A Structural Dynamic Explanation for Observed Escape of SARS-CoV-2 BA.2 Variant Mutation S371L\/F. bioRxiv.","DOI":"10.1101\/2022.02.25.481957"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2666-5247(22)00060-X","article-title":"Serum Neutralisation of the SARS-CoV-2 Omicron Sublineage BA.2","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lee, H.K., Knabl, L., Walter, M., Furth, P.A., and Hennighausen, L. (2022). Limited Cross-Variant Immune Response from SARS-CoV-2 Omicron BA.2 in Na\u00efve but Not Previously Infected Outpatients. MedRxiv.","DOI":"10.1101\/2022.04.07.22273565"},{"key":"ref_28","unstructured":"European Centre for Disease Prevention and Control (2022, June 09). Weekly Epidemiological Update on COVID-19. 1 June 2022. Available online: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---1-june-2022."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Xu, Y., Wu, C., Cao, X., Gu, C., Liu, H., Jiang, M., Wang, X., Yuan, Q., Wu, K., and Liu, J. (2022). Structural and Biochemical Mechanism for Increased Infectivity and Immune Evasion of Omicron BA.2 Variant Compared to BA.1 and Their Possible Mouse Origins. Cell Res., in press.","DOI":"10.1101\/2022.04.12.488075"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lyngse, F.P., Kirkeby, C.T., Denwood, M., Christiansen, L.E., M\u00f8lbak, K., M\u00f8ller, C.H., Skov, R.L., Krause, T.G., Rasmussen, M., and Sieber, R.N. (2022). Transmission of SARS-CoV-2 Omicron VOC Subvariants BA.1 and BA.2: Evidence from Danish Households. MedRxiv.","DOI":"10.1101\/2022.01.28.22270044"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Barre, A., Klonjkowski, B., Benoist, H., and Roug\u00e9, P. (2022). How Do Point Mutations Enhancing the Basic Character of the RBDs of SARS-CoV-2 Variants Affect Their Transmissibility and Infectivity Capacities?. Viruses, 14.","DOI":"10.3390\/v14040783"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1021\/acs.jpclett.2c00469","article-title":"Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant","volume":"13","author":"Chen","year":"2022","journal-title":"J. Phys. Chem. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Qassim, S.H., Chemaitelly, H., Ayoub, H.H., AlMukdad, S., Tang, P., Hasan, M.R., Yassine, H.M., Al-Khatib, H.A., Smatti, M.K., and Abdul-Rahim, H.F. (2022). Effects of BA.1\/BA.2 Subvariant, Vaccination, and Prior Infection on Infectiousness of SARS-CoV-2 Omicron Infections. J. Travel Med.","DOI":"10.1101\/2022.03.02.22271771"},{"key":"ref_34","unstructured":"Cheng, V.C.-C., Ip, J.D., Chu, A.W.-H., Tam, A.R., Chan, W.-M., Abdullah, S.M.U., Chan, B.P.-C., Wong, S.-C., Kwan, M.Y.-W., and Chua, G.T. (2022). Rapid Spread of SARS-CoV-2 Omicron Subvariant BA.2 in a Single-Source Community Outbreak. Clin. Infect. Dis., in press."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/22221751.2021.2023329","article-title":"SARS-CoV-2 Omicron Variant Shows Less Efficient Replication and Fusion Activity When Compared with Delta Variant in TMPRSS2-Expressed Cells","volume":"11","author":"Zhao","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_36","unstructured":"WHO (2022, June 10). Statement on Omicron Sublineage BA.2. Available online: https:\/\/www.who.int\/news\/item\/22-02-2022-statement-on-omicron-sublineage-ba.2."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Uraki, R., Kiso, M., Imai, M., Yamayoshi, S., Ito, M., Ujie, M., Furusawa, Y., Iwatsuki-Horimoto, K., Sakai-Tagawa, Y., and Kawaoka, Y. (2022). Therapeutic Efficacy of Antibodies and Antivirals against a SARS-CoV-2 Omicron Variant. Res. Sq., in press.","DOI":"10.21203\/rs.3.rs-1240227\/v1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gautret, P., Hoang, V.T., Jimeno, M.T., Lagier, J.-C., Rossi, P., Fournier, P.E., Colson, P., and Raoult, D. (2022). The Severity of the First 207 Infections with the SARS-CoV-2 Omicron BA.2 Variant, in Marseille, France, December 2021\u2013February 2022. J. Med. Virol.","DOI":"10.1002\/jmv.27760"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.14740\/jocmr4671","article-title":"What Is New With Omicron Variant of SARS-CoV-2 in Children?","volume":"14","author":"Bittmann","year":"2022","journal-title":"J. Clin. Med. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3201\/eid2807.220470","article-title":"University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022","volume":"28","author":"Fowle","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_41","first-page":"2200396","article-title":"SARS-CoV-2 Omicron Variants BA.1 and BA.2 Both Show Similarly Reduced Disease Severity of COVID-19 Compared to Delta, Germany, 2021 to 2022","volume":"27","author":"Sievers","year":"2022","journal-title":"Eurosurveillance Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_42","unstructured":"Zimmer, C., and \u2018Stealth\u2019 Omicron Is Stealthy No More: What\u2019s Known about the BA.2 Variant (2022, June 09). New York Times, 18 March 2022, Available online: https:\/\/www.ncbi.nlm.nih.gov\/search\/research-news\/15717\/?utm_source=gquery&utm_medium=referral&utm_campaign=gquery-home."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/jcm.00600-22","article-title":"Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1","volume":"60","author":"Rodino","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e02479-21","DOI":"10.1128\/jcm.02479-21","article-title":"Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2 Omicron Variant","volume":"60","author":"Deerain","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mak, G.C.K., Lau, S.S.Y., Wong, K.K.Y., Lau, C.S., Ng, K.H.L., Lam, E.T.K., and Chan, R.C.W. (2022). Analytical Sensitivity of the Rapid Antigen Test Kits for Detection of SARS-CoV-2 Omicron Variant BA.2 Sub-Lineage. J. Med. Virol.","DOI":"10.1002\/jmv.27908"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ohashi, H., Hishiki, T., Akazawa, D., Kim, K.S., Woo, J., Shionoya, K., Tsuchimoto, K., Iwanami, S., Moriyama, S., and Kinoshita, H. (2022). Different Efficacies of Neutralizing Antibodies and Antiviral Drugs on SARS-CoV-2 Omicron Subvariants, BA.1 and BA.2. BioRxiv.","DOI":"10.1101\/2022.02.27.482147"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Quiros-Roldan, E., Amadasi, S., Zanella, I., Degli Antoni, M., Storti, S., Tiecco, G., and Castelli, F. (2021). Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Pharmaceuticals, 14.","DOI":"10.3390\/ph14121272"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Javanmardi, K., Segall-Shapiro, T.H., Chou, C.-W., Boutz, D.R., Olsen, R.J., Xie, X., Xia, H., Shi, P.-Y., Johnson, C.D., and Annapareddy, A. (2022). Antibody Escape and Cryptic Cross-Domain Stabilization in the SARS CoV-2 Omicron Spike Protein. BioRxiv.","DOI":"10.1101\/2022.04.18.488614"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ai, J., Wang, X., He, X., Zhao, X., Zhang, Y., Jiang, Y., Li, M., Cui, Y., Chen, Y., and Qiao, R. (2022). Antibody Evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 Sub-Lineages. Cell Host Microbe, in press.","DOI":"10.1101\/2022.04.07.487489"},{"key":"ref_52","unstructured":"Food and Drug Administration (2022, June 09). FDA Updates Sotrovimab Emergency Use Authorization, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-sotrovimab-emergency-use-authorization."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"o1009","DOI":"10.1136\/bmj.o1009","article-title":"Covid-19: Has the Spread of Omicron BA.2 Made Antibody Treatments Redundant?","volume":"377","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhou, H., Tada, T., Dcosta, B.M., and Landau, N.R. (2022). Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies. BioRxiv.","DOI":"10.1101\/2022.02.15.480166"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Arora, P., Zhang, L., Kr\u00fcger, N., Rocha, C., Sidarovich, A., Schulz, S., Kempf, A., Graichen, L., Moldenhauer, A.-S., and Cossmann, A. (2022). SARS-CoV-2 Omicron Sublineages Show Comparable Cell Entry but Differential Neutralization by Therapeutic Antibodies. Cell Host Microbe, in press.","DOI":"10.1016\/j.chom.2022.04.017"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dacon, C., Tucker, C., Peng, L., Lee, C.-C.D., Lin, T.-H., Yuan, M., Cong, Y., Wang, L., Purser, L., and Williams, J.K. (2022). Broadly Neutralizing Antibodies Target the Coronavirus Fusion Peptide. BioRxiv.","DOI":"10.1126\/science.abq3773"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Westendorf, K., \u017dentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., and Pustilnik, A. (2022). LY-CoV1404 (Bebtelovimab) Potently Neutralizes SARS-CoV-2 Variants. BioRxiv.","DOI":"10.1016\/j.celrep.2022.110812"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3201\/eid2806.220503","article-title":"Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination","volume":"28","author":"Pedersen","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bowen, J.E., Sprouse, K.R., Walls, A.C., Mazzitelli, I.G., Logue, J.K., Franko, N.M., Ahmed, K., Shariq, A., Cameroni, E., and Gori, A. (2022). Omicron BA.1 and BA.2 Neutralizing Activity Elicited by a Comprehensive Panel of Human Vaccines. BioRxiv.","DOI":"10.1101\/2022.03.15.484542"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1473-3099(22)00309-7","article-title":"COVID-19 Vaccine Effectiveness against the Omicron (BA.2) Variant in England","volume":"22","author":"Kirsebom","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1038\/s41467-022-30895-3","article-title":"Duration of MRNA Vaccine Protection against SARS-CoV-2 Omicron BA.1 and BA.2 Subvariants in Qatar","volume":"13","author":"Chemaitelly","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.cell.2022.03.037","article-title":"Boosting with Variant-Matched or Historical MRNA Vaccines Protects against Omicron Infection in Mice","volume":"185","author":"Ying","year":"2022","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"MRNA-1273 or MRNA-Omicron Boost in Vaccinated Macaques Elicits Similar B Cell Expansion, Neutralizing Responses, and Protection from Omicron","volume":"185","author":"Gagne","year":"2022","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Motozono, C., Toyoda, M., Tan, T.S., Hamana, H., Aritsu, Y., Miyashita, Y., Oshiumi, H., Nakamura, K., Okada, S., and Udaka, K. (2022). The SARS-CoV-2 Omicron BA.1 Spike G446S Potentiates HLA-A*24:02-Restricted T Cell Immunity. BioRxiv.","DOI":"10.1101\/2022.04.17.488095"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1002\/jmv.27749","article-title":"\u201cIs Omicron Mild\u201d? Testing This Narrative with the Mutational Landscape of Its Three Lineages and Response to Existing Vaccines and Therapeutic Antibodies","volume":"94","author":"Rajpal","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"de Souza, A.S., de Freitas, V.M.A., Guardia, G.D.A., Dos Santos, F.F., Ulrich, H., Galante, P.A.F., de Souza, R.F., and Guzzo, C.R. (2022). Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. Viruses, 14.","DOI":"10.20944\/preprints202202.0261.v1"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1016\/S2666-5247(22)00119-7","article-title":"Co-Infection with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariants in a Non-Vaccinated Woman","volume":"3","author":"Vatteroni","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3201\/eid2806.220523","article-title":"Recombinant BA.1\/BA.2 SARS-CoV-2 Virus in Arriving Travelers, Hong Kong, February 2022","volume":"28","author":"Gu","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lacek, K.A., Rambo-Martin, B.L., Batra, D., Zheng, X., Sakaguchi, H., Peacock, T., Keller, M., Wilson, M.M., Sheth, M., and Davis, M.L. (2022). Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United States. BioRxiv.","DOI":"10.1101\/2022.03.19.484981"},{"key":"ref_71","unstructured":"GISAID (2022, June 10). HCov19 Variants. Available online: https:\/\/www.gisaid.org\/Hcov19-Variants\/."},{"key":"ref_72","unstructured":"ECDC (2022, June 09). SARS-CoV-2 Variants of Concern as of 7 April. Available online: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern."},{"key":"ref_73","first-page":"2200257","article-title":"Genomic and Epidemiological Report of the Recombinant XJ Lineage SARS-CoV-2 Variant, Detected in Northern Finland, January 2022","volume":"27","author":"Lindh","year":"2022","journal-title":"Eurosurveillance Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_74","unstructured":"WHO (2022, June 10). Botswana, South Africa Deepen Probe into New Omicron Sub-Variants. Available online: https:\/\/www.afro.who.int\/news\/botswana-south-africa-deepen-probe-new-omicron-sub-variants."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:41:21Z","timestamp":1760139681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":74,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23137315"],"URL":"https:\/\/doi.org\/10.3390\/ijms23137315","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}